1. Home
  2. YMT vs MOLN Comparison

YMT vs MOLN Comparison

Compare YMT & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

YMT

Yimutian Inc. American Depositary Shares

N/A

Current Price

$1.57

Market Cap

172.7M

Sector

Technology

ML Signal

N/A

Logo Molecular Partners AG

MOLN

Molecular Partners AG

N/A

Current Price

$4.36

Market Cap

164.2M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
YMT
MOLN
Founded
2011
2004
Country
China
Switzerland
Employees
N/A
N/A
Industry
EDP Services
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
172.7M
164.2M
IPO Year
2025
2021

Fundamental Metrics

Financial Performance
Metric
YMT
MOLN
Price
$1.57
$4.36
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
$3.75
AVG Volume (30 Days)
54.0K
4.4K
Earning Date
06-09-2026
02-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$20,502,945.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$999.99
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.00
$3.36
52 Week High
$6.05
$5.91

Technical Indicators

Market Signals
Indicator
YMT
MOLN
Relative Strength Index (RSI) N/A 52.51
Support Level N/A $4.16
Resistance Level N/A $4.44
Average True Range (ATR) 0.00 0.17
MACD 0.00 -0.01
Stochastic Oscillator 0.00 64.50

Price Performance

Historical Comparison
YMT
MOLN

About YMT Yimutian Inc. American Depositary Shares

Yimutian Inc is the largest agricultural B2B platform in mainland China. It provide a comprehensive set of digital solutions to facilitate agricultural product transactions, ranging from searching, matching, to transaction facilitation and settlement. The company pride itself as the go-to platform for merchants by leveraging its inventive technology and industry know-how. Its platform had over 38 million merchants. It has also established approximately 12 offline stores in mainland China to trade agricultural products at cultivation and production sites with sellers and buyers.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Share on Social Networks: